Characteristic
Patients (N=106) (% of total)
Gender
Female 42 (39.6)
Male 64 (60.4)
Age
≥ 20 years 68 (64.2)
< 20 years 38 (35.8)
Race
White 97 (91.5)
Black 2 (1.9)
Multi-Racial 2 (1.9)
Declined/Unavailable 5 (4.7)
Ethnicity
Hispanic or Latino 4 (3.8)
Genotype
Homozygous F508del 62 (58.5)
Heterozygous F508del 44 (41.5)
Lung Function1
Normal (FEV1 ≥ 90% Percent Predicted) 39 (31.5)
Mild (70-89%) 22 (17.7)
Moderate (40-69%) 25 (20.2)
Severe (<40%) 16 (12.9)
Previous Modulator Use
Ivacaftor 12 (11.3)
Lumacaftor/Ivacaftor 48 (45.3)
Tezacaftor/Ivacaftor 18 (17.0)
None 28 (26.4)
Pancreatic Insufficient 92 (86.8)
CFRD2 15 (14.2)
GERD3 60 (56.6)
Consuming Nutritional Supplements 26 (24.5)
Oral 24 (19.4)
Tube
(1.6)